(COV) Covivio - Ratings and Ratios
Office Buildings, Hotels, Residential
Description: COV Covivio
Covivio SA is a prominent European real estate company that focuses on creating user-centric experiences and designing sustainable cities. With €23.1 billion in assets, the company is well-positioned to address the needs of companies, hotel brands, and local authorities, while prioritizing attractiveness, transformation, and responsible performance.
From a financial perspective, Covivios market capitalization stands at €6.12 billion, with a forward price-to-earnings ratio of 12.27, indicating a relatively stable valuation. The companys return on equity (ROE) is -16.36%, suggesting that it may be facing challenges in generating profits. However, its inclusion in various ESG indices, such as FTSE4 Good, CAC SBT1.5°C, and DJSI World, highlights its commitment to sustainability and responsible practices.
Some key performance indicators (KPIs) to monitor Covivios performance include its funds from operations (FFO) growth, net operating income (NOI) margin, and debt-to-equity ratio. The companys ability to maintain a strong occupancy rate and increase its rental income will be crucial in driving its financial performance. Additionally, Covivios focus on sustainability and ESG initiatives may lead to long-term benefits, such as reduced operating costs and enhanced brand reputation.
Covivios listing on Euronext Paris and inclusion in various indices, such as the MSCI and SBF120, provides liquidity and visibility for investors. The companys commitment to transparency and sustainability is reflected in its EPRA BPRs Gold Awards and GRESB rating of 88/100. As a diversified REIT, Covivios portfolio is well-positioned to benefit from trends in the European real estate market, including the growing demand for sustainable and user-centric properties.
COV Stock Overview
| Market Cap in USD | 7,410m |
| Sub-Industry | Diversified REITs |
| IPO / Inception |
COV Stock Ratings
| Growth Rating | 30.8% |
| Fundamental | 64.2% |
| Dividend Rating | 25.5% |
| Return 12m vs S&P 500 | -8.30% |
| Analyst Rating | - |
COV Dividends
| Dividend Yield 12m | 4.66% |
| Yield on Cost 5y | 5.67% |
| Annual Growth 5y | -7.22% |
| Payout Consistency | 91.5% |
| Payout Ratio | 92.8% |
COV Growth Ratios
| Growth Correlation 3m | 65.4% |
| Growth Correlation 12m | 50.7% |
| Growth Correlation 5y | -41.7% |
| CAGR 5y | 13.56% |
| CAGR/Max DD 3y | 0.33 |
| CAGR/Mean DD 3y | 0.82 |
| Sharpe Ratio 12m | 0.73 |
| Alpha | 0.02 |
| Beta | 0.869 |
| Volatility | 23.63% |
| Current Volume | 136k |
| Average Volume 20d | 106.7k |
| Stop Loss | 55 (-3.2%) |
| Signal | -0.29 |
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income (-319.5m TTM) > 0 and > 6% of Revenue (6% = 150.2m TTM) |
| FCFTA 0.03 (>2.0%) and ΔFCFTA 2.49pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -3.16% (prev -18.33%; Δ 15.17pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 1.81b > Net Income -319.5m (YES >=105%, WARN >=100%) |
| Net Debt (10.84b) to EBITDA (1.50b) ratio: 7.22 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.96 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (110.8m) change vs 12m ago 16.81% (target <= -2.0% for YES) |
| Gross Margin 64.69% (prev 74.76%; Δ -10.07pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 9.59% (prev 5.57%; Δ 4.02pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 7.71 (EBITDA TTM 1.50b / Interest Expense TTM 166.3m) >= 6 (WARN >= 3) |
Altman Z'' 0.63
| (A) -0.00 = (Total Current Assets 2.17b - Total Current Liabilities 2.25b) / Total Assets 25.63b |
| (B) 0.00 = Retained Earnings (Balance) 68.1m / Total Assets 25.63b |
| (C) 0.05 = EBIT TTM 1.28b / Avg Total Assets 26.10b |
| (D) 0.30 = Book Value of Equity 4.06b / Total Liabilities 13.61b |
| Total Rating: 0.63 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 64.22
| 1. Piotroski 3.0pt = -2.0 |
| 2. FCF Yield 4.62% = 2.31 |
| 3. FCF Margin 30.43% = 7.50 |
| 4. Debt/Equity 1.41 = 1.58 |
| 5. Debt/Ebitda 7.71 = -2.50 |
| 6. ROIC - WACC (= 2.01)% = 2.51 |
| 7. RoE -3.93% = -0.65 |
| 8. Rev. Trend 41.62% = 3.12 |
| 9. EPS Trend 47.07% = 2.35 |
What is the price of COV shares?
Over the past week, the price has changed by +1.34%, over one month by -2.99%, over three months by +10.18% and over the past year by +8.69%.
Is Covivio a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of COV is around 56.78 EUR . This means that COV is currently overvalued and has a potential downside of -0.04%.
Is COV a buy, sell or hold?
What are the forecasts/targets for the COV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 63.4 | 11.6% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 60.8 | 7% |
COV Fundamental Data Overview
Market Cap EUR = 6.27b (6.27b EUR * 1.0 EUR.EUR)
CCE Cash And Equivalents = 1.36b EUR (Cash And Short Term Investments, last quarter)
P/E Trailing = 15.0133
P/E Forward = 11.6414
P/S = 5.5094
P/B = 0.7607
Beta = 1.365
Revenue TTM = 2.50b EUR
EBIT TTM = 1.28b EUR
EBITDA TTM = 1.50b EUR
Long Term Debt = 9.16b EUR (from longTermDebt, last fiscal year)
Short Term Debt = 2.42b EUR (from shortTermDebt, last quarter)
Debt = 11.58b EUR (Calculated: Short Term 2.42b + Long Term 9.16b)
Net Debt = 10.84b EUR (from netDebt column, last quarter)
Enterprise Value = 16.49b EUR (6.27b + Debt 11.58b - CCE 1.36b)
Interest Coverage Ratio = 7.71 (Ebit TTM 1.28b / Interest Expense TTM 166.3m)
FCF Yield = 4.62% (FCF TTM 761.7m / Enterprise Value 16.49b)
FCF Margin = 30.43% (FCF TTM 761.7m / Revenue TTM 2.50b)
Net Margin = -12.76% (Net Income TTM -319.5m / Revenue TTM 2.50b)
Gross Margin = 64.69% ((Revenue TTM 2.50b - Cost of Revenue TTM 883.8m) / Revenue TTM)
Tobins Q-Ratio = 4.06 (Enterprise Value 16.49b / Book Value Of Equity 4.06b)
Interest Expense / Debt = 1.44% (Interest Expense 166.3m / Debt 11.58b)
Taxrate = 10.64% (23.5m / 220.9m)
NOPAT = 1.15b (EBIT 1.28b * (1 - 10.64%))
Current Ratio = 0.96 (Total Current Assets 2.17b / Total Current Liabilities 2.25b)
Debt / Equity = 1.41 (Debt 11.58b / last Quarter total Stockholder Equity 8.22b)
Debt / EBITDA = 7.71 (Net Debt 10.84b / EBITDA 1.50b)
Debt / FCF = 15.20 (Debt 11.58b / FCF TTM 761.7m)
Total Stockholder Equity = 8.14b (last 4 quarters mean)
RoA = -1.25% (Net Income -319.5m, Total Assets 25.63b )
RoE = -3.93% (Net Income TTM -319.5m / Total Stockholder Equity 8.14b)
RoCE = 7.41% (Ebit 1.28b / (Equity 8.14b + L.T.Debt 9.16b))
RoIC = 6.08% (NOPAT 1.15b / Invested Capital 18.84b)
WACC = 4.07% (E(6.27b)/V(17.85b) * Re(9.22%)) + (D(11.58b)/V(17.85b) * Rd(1.44%) * (1-Tc(0.11)))
Shares Correlation 3-Years: 48.08 | Cagr: 1.41%
Discount Rate = 9.22% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 71.12% ; FCFE base≈508.4m ; Y1≈431.9m ; Y5≈330.7m
Fair Price DCF = 44.71 (DCF Value 4.95b / Shares Outstanding 110.8m; 5y FCF grow -18.26% → 3.0% )
EPS Correlation: 47.07 | EPS CAGR: 40.72% | SUE: 0.62 | # QB: 0
Revenue Correlation: 41.62 | Revenue CAGR: 9.13% | SUE: N/A | # QB: None